60 Biggest Movers From Yesterday
Gainers
Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday.
See Why Lixte Biotech Shares Trading At Over 100%?
In preclinical studies, Lixte Biotechnology Holdings Inc's (NASDAQ: LIXT) lead clinical compound, LB-100,
Lixte Biotechnology’s LB-100 Reported To Convert Immunologically Unresponsive Tumors To Immunologically Responsive Tumors
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced today that in preclinical studies its
Lixte Biotechnology Announces Collaboration With Netherlands Cancer Institute, Oncode Institute To ‘Identify The Most Promising Drug Combinations For Its Lead Clinical Compound, LB-100, For Cancer Treatment’
- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced entry into a collaboration with the Netherlands Cancer Institute, Amsterdam (NKI) , one of the world's leading comprehensive
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)